Literature DB >> 20335412

Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and JustOne strips.

N Esther Babady1, Leslie Hall, Adeline T Abbenyi, Justin J Eisberner, Barbara A Brown-Elliott, Cody J Pratt, Maria C McGlasson, Keanan D Beierle, Sherri L Wohlfiel, Sharon M Deml, Richard J Wallace, Nancy L Wengenack.   

Abstract

The SLOMYCO Sensititre panel and the custom JustOne strip (both from TREK Diagnostic Systems, Cleveland, OH) were evaluated for susceptibility testing of Mycobacterium avium complex isolates against clarithromycin. Seventy-one archived and prospectively collected isolates were tested using both the SLOMYCO panel and the JustOne strip, and the results were compared to those obtained using the BACTEC 460 (BD, Sparks, MD) radiometric method and a broth microdilution reference method. Results obtained by the SLOMYCO panel and the JustOne strip agreed with the BACTEC 460 method for 64/71 isolates (90%). Similarly, concordance with the broth microdilution method was 40/43 isolates (93%) for both test systems. The effect of the source medium on inoculum preparation was evaluated, and there were no differences noted in MICs, regardless of whether the inoculum was prepared from isolates grown in Middlebrook 7H9 medium, on Middlebrook 7H10 agar, or in VersaTREK broth culture bottles (Trek Diagnostics). Clarithromycin susceptibility testing of MAC using the SLOMYCO panel and the JustOne strip methods is easy to set up and simple to read and is readily incorporate into the clinical laboratory. These systems offer advantages over the BACTEC 460 system including the lack of a need for radioactive substrates, sharps, or costly instrumentation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335412      PMCID: PMC2863902          DOI: 10.1128/JCM.01936-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

3.  The expanding spectrum of Mycobacterium avium complex-associated pulmonary disease.

Authors:  E Andrew Waller; Archana Roy; Lisa Brumble; Andras Khoor; Margaret M Johnson; Jeffrey L Garland
Journal:  Chest       Date:  2006-10       Impact factor: 9.410

4.  PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria.

Authors:  V A Steingrube; J L Gibson; B A Brown; Y Zhang; R W Wilson; M Rajagopalan; R J Wallace
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

5.  Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.

Authors:  R E Chaisson; C A Benson; M P Dube; L B Heifets; J A Korvick; S Elkin; T Smith; J C Craft; F R Sattler
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

6.  Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients.

Authors:  B Ruf; D Schürmann; H Mauch; G Jautzke; F J Fehrenbach; H D Pohle
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

Review 7.  Diagnosis and treatment of lung infection with nontuberculous mycobacteria.

Authors:  Sandra M Arend; Dick van Soolingen; Tom H M Ottenhoff
Journal:  Curr Opin Pulm Med       Date:  2009-05       Impact factor: 3.155

8.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
  8 in total
  7 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates.

Authors:  Simone Mok; Margaret M Hannan; Lars Nölke; Patrick Stapleton; Niamh O'Sullivan; Philip Murphy; Anne Marie McLaughlin; Eleanor McNamara; Margaret M Fitzgibbon; Thomas R Rogers
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease.

Authors:  Yong Pil Chong; Kyung-Wook Jo; Byoung Soo Kwon; Mi-Na Kim; Heungsup Sung; Younsuck Koh; Woo-Sung Kim; Jin-Woo Song; Yeon-Mok Oh; Sang-Do Lee; Sei Won Lee; Jae-Seung Lee; Chae-Man Lim; Chang-Min Choi; Jin-Won Huh; Sang-Bum Hong; Sojung Park; Tae Sun Shim
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 4.  Highlight on advances in nontuberculous mycobacterial disease in North America.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Mary Beth Allen; Golnaz Ebrahimi; Joseph O Falkinham
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

5.  Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.

Authors:  Venkata Raveendra Pothineni; Dhananjay Wagh; Mustafeez Mujtaba Babar; Mohammed Inayathullah; David Solow-Cordero; Kwang-Min Kim; Aneesh V Samineni; Mansi B Parekh; Lobat Tayebi; Jayakumar Rajadas
Journal:  Drug Des Devel Ther       Date:  2016-04-01       Impact factor: 4.162

6.  Evaluation of the SLOMYCO Sensititre(®) panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates.

Authors:  Marion Chazel; Hélène Marchandin; Nicolas Keck; Dominique Terru; Christian Carrière; Michael Ponsoda; Véronique Jacomo; Gilles Panteix; Nicolas Bouzinbi; Anne-Laure Bañuls; Marc Choisy; Jérôme Solassol; Alexandra Aubry; Sylvain Godreuil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-06       Impact factor: 3.944

7.  Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.

Authors:  Vitalii Litvinov; Marina Makarova; Ksenia Galkina; Elena Khachaturiants; Maria Krasnova; Lidia Guntupova; Svetlana Safonova
Journal:  PLoS One       Date:  2018-09-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.